



**UNIVERSIDADE FEDERAL DO AMAPÁ  
PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS FARMACÊUTICAS**

**RAIMUNDO DE ALMEIDA MIRA NETO**

---

---

**Avaliação da atividade antineoplásica de chalconas sintéticas  
utilizando modelos de glioblastomas *in vitro* e docking molecular  
para topoisomerase-II- $\alpha$  e tubulina**

---

---

**Macapá  
2018**

**RAIMUNDO DE ALMEIDA MIRA NETO**

---

**Avaliação da atividade antineoplásica de chalconas sintéticas  
utilizando modelos de glioblastomas *in vitro* e docking molecular para  
topoisomerase-II- $\alpha$  e tubulina**

---

Dissertação apresentada ao Programa de Pós-Graduação em Ciências Farmacêuticas da Universidade Federal do Amapá para obtenção do Título de Mestre em Ciências Farmacêuticas.

Orientador: Dr. Madson Ralide Fonseca Gomes

**Macapá  
2018**

Dados Internacionais de Catalogação na Publicação (CIP)  
Biblioteca Central da Universidade Federal do Amapá

615.1

M671a Mira Neto, Raimundo de Almeida

**1.1.1.** *Avaliação da atividade antineoplásica de chalconas sintéticas utilizando modelos de glioblastomas In vitro e docking molecular para Topoisomerase-II- $\alpha$  e Tubulina / Raimundo de Almeida Mira Neto; orientador, Madson Ralide Fonseca Gomes. – Macapá, 2018.*

55 f.

Dissertação (Mestrado) – Fundação Universidade Federal do Amapá, Programa de Pós-Graduação em Ciências Farmacêuticas.

1. Chalconas - Avaliação - Uso terapêutico. 2. Câncer -

**Programa de Pós-Graduação em Ciências Farmacêuticas  
da Universidade Federal do Amapá**

**BANCA EXAMINADORA**


**Aluno(a): Raimundo de Almeida Mira Neto**

---

**Orientador(a): Prof. Dr. Madson Ralide Fonseca Gomes**

---

**Co-Orientador(a):**

  
**Prof. Dr. Madson Ralide Fonseca Gomes / Presidente**  
Professor Titular do Curso de Farmácia da Universidade Federal do Amapá, UNIFAP.

  
**Prof. Dra. Mayara Tânia Pinheiro / Membro Titular**  
Professor Titular do Curso de Farmácia da Universidade Federal do Amapá, UNIFAP.

  
**Prof. Dra. Lorane Izabel da Silva Hage Melim / Membro Titular**  
Professor Titular do Curso de Farmácia da Universidade Federal do Amapá, UNIFAP.

**Data: 23/04/2018**

***Dedico este trabalho a minha família.***

## AGRADECIMENTOS

---

*Primeiramente agradeço a Deus pelo ingresso no programa de pós-graduação em Ciências Farmacêuticas, por todas as matérias cursadas e por todo o trabalho executado, pois tudo foi na graça de Deus.*

*Agradeço a minha esposa Thayse Alencar Mira, companheira fiel e paciente nessa jornada, jamais me permitiu desistir. Agradeço seu amor que muitas vezes me apoiou.*

*Agradeço a meus Pais Edson Pinheiro e Eliana Pinheiro pelo apoio e incentivo, que também jamais me permitiu desistir e sempre me fizeram acreditar nesse caminho acadêmico.*

*Agradeço ao meu orientador professor Madson Ralide, por sua pronta disposição em me orientar. Sempre foi um orientador presente e jamais deixou este estudo sem amparo.*

*Agradeço ao professor Irlom Maciel e sua equipe que nos forneceu as moléculas de chalconas. Agradeço o professor Breno Santos por sua orientação e ensinamento nos estudos in silico. Agradeço o professor Edivaldo Herculano e sua equipe que forneceu a estrutura de seu laboratório para execução dos testes in vitro, e por todo o conhecimento adquirido com sua equipe.*

<b>1</b>	<b>INTRODUÇÃO.....</b>	<b>1</b>
1.1	CÂNCER.....	1
1.2	GLIOBLASTOMA.....	2
1.3	PLANEJAMENTO E DESENVOLVIMENTO DE FARMACOS ANTINEOPLÁSICOS.....	4
1.4	TOPOISOMERASE-II- $\alpha$ E TUBULINA.....	6
1.5	CHALCONAS.....	7
<b>2</b>	<b>OBJETIVOS.....</b>	<b>8</b>
2.1	OBJETIVO GERAL.....	8
2.2	OBJETIVOS ESPECÍFICOS.....	8
<b>3</b>	<b>ARTIGO 1: EVALUATION OF ANTINEOPLASTIC ACTIVITY OF SYNTHETIC CHALCONES USING IN VITRO GLIOBLASTOMA AND MOLECULAR DOCKING MODELS FOR TOPOISOMERASE-II-<math>\alpha</math> AND TUBULIN.....</b>	<b>8</b>
<b>4</b>	<b>CONSIDERAÇÕES FINAIS E PERSPECTIVAS .....</b>	<b>37</b>
	<b>REFERÊNCIAS .....</b>	<b>38</b>
	<b>ANEXOS .....</b>	<b>41</b>

### **Avaliação da atividade antineoplásica de chalconas sintéticas utilizando modelos de glioblastomas *in vitro* e docking molecular para topoisomerase-II- $\alpha$ e tubulina**

#### **RESUMO**

**Introdução:** O glioblastoma é um tumor maligno com baixa taxa de sobrevivência, possui rápido crescimento e tem uma alta taxa de rotatividade celular. Estudos visando o desenvolvimento de novos fármacos anticancerígenos tem aumentado, a predição do modo de ancoragem de moléculas promissoras ao sitio de interesse é primordial no design racional de drogas. **Objetivo:** Esse estudo avaliou a atividade antineoplásica de chalconas sintéticas utilizando modelos de glioblastomas *in vitro* e propôs por docking molecular o sitio de ação dessas moléculas. **Metodologia:** as chalconas foram sintetizadas e analisadas por cromatografia gasosa acoplada ao espectro de massas, a viabilidade celular foi investigada pelo teste do MTT e o estudo de docking molecular foi realizado no software GOLD. **Resultados e discussões:** Os resultados do ensaio MTT mostraram que as células AHOL1 e U87 tiveram sua viabilidade celular reduzida quando expostas as chalconas analisadas apresentando diferença significativa ( $p < 0,0001$ ) quando comparadas a linhagem sadia AN27. A análise comparativa das interações das moléculas com o alvo TOPIIA identificou interações em serina (SER148-149) e isoleucina (ILE125). A interação com o aminoácido serina estava presente tanto no docking dos ligantes mais promissores quanto nos de referência, sugerindo sua importância no efeito inibitório do crescimento celular. A análise comparativa entre os ligantes de referência e as moléculas em estudos identificou o aminoácido LYS 352 presente em todos os encaixes, sugerindo que esse seja o principal aminoácido para a interação com a tubulina, observou-se também que a ausência de interação com o aminoácido CYS 241 provoca redução no gold score. **Conclusões:** Os resultados obtidos no docking molecular corroboram com o observado no MTT, sugerindo que as moléculas em estudo possuem potencial antineoplásico em glioblastomas.

**Palavras-Chave:** *Chalconas; Citotoxicidade; Docking molecular; Topoisomerase II alfa; Tubulina.*

### Evaluation of antineoplastic activity of synthetic chalcones using *in vitro* glioblastomas models and molecular docking for topoisomerase-II- $\alpha$ and tubulin

#### ABSTRACT

**Introduction:** Glioblastoma is a malignant tumor with low survival rate, has rapid growth and has a high turnover rate. Studies aiming at the development of new anticancer drugs have increased, predicting the mode of anchoring promising molecules to the site of interest is paramount in rational drug design. **Purpose:** This study evaluated the antineoplastic activity of synthetic chalcones using *in vitro* glioblastomas models and proposed by molecular docking the site of action of these molecules. **Methodology:** chalcones were synthesized and analyzed by gas chromatography coupled to the mass spectra, cell viability was investigated by the MTT test and the molecular docking study was performed in the GOLD software. **Results and discussion:** The results of the MTT assay showed that the AHOL1 and U87 cells had their cell viability reduced when the chalcones analyzed were exposed, presenting a significant difference ( $p < 0.0001$ ) when compared to the AN27 healthy lineage. The comparative analysis of the interactions of the molecules with the TOPIIA target identified interactions in serine (SER148-149) and isoleucine (ILE125). Interaction with the serine amino acid was present in both the most promising and the reference binder docking, suggesting its importance in the inhibitory effect of cell growth. Comparative analysis between the reference ligands and the molecules in studies identified the amino acid LYS 352 present in all of the inserts, suggesting that this is the main amino acid for interaction with tubulin, it was also observed that the absence of interaction with the amino acid CYS 241 causes reduction in the gold score. **Conclusions:** The results obtained in the molecular docking corroborate with that observed in MTT, suggesting that the molecules under study have antineoplastic potential in glioblastomas.

**Keywords:** Chalconas; Cytotoxicity; Molecular docking; Topoisomerase II alpha; Tubulin.

## 1.1 CÂNCER

As células somáticas acumulam mutações que podem conferir vantagem seletiva à célula, como o aumentando da sobrevivência ou proliferação, as que são seletivamente neutras e as mutações que são desvantagens para a célula e resultam em sua morte. O câncer é produto da evolução somática, em que uma única linhagem clonal adquire mutações que permitem a superação de restrições normais à proliferação celular, invadem os tecidos e se espalham para outros órgãos (MARTINCORENA et al., 2017).

O sequenciamento de todo o genoma e as tecnologias massivamente paralelas permitiram entender que o câncer é uma doença causada principalmente por alterações genômicas, especialmente as mutações de células somáticas. O desenvolvimento do câncer é impulsionado pela acumulação de alterações que afetam a estrutura e a função do genoma. Estas alterações são frequentemente adquiridas como resultado da exposição a múltiplos agentes carcinogênicos, afetando não apenas o funcionamento das proteínas codificadas pelos genes alterados, mais também todo o circuito que controla o crescimento celular, o potencial replicativo, a sobrevivência e a resposta ao estresse. Dentre esses processos, incluem danos oxidativos, erros na ação das polimerases e recombinases, redução e reordenamento cromossômico. (SILVA; RIUL, 2011; ZHAO et al., 2015).

Desse modo, o termo câncer é designado a mais de uma centena de diferentes doenças heterogêneas do material genético que promovem alterações essenciais na fisiologia celular. A carcinogênese resulta de processos multifatoriais, que incluem a interação de fatores genéticos e agentes carcinógenos externos, físicos (ultravioleta e radiação ionizante), químicos (pesticidas, herbicidas, ou contaminantes de água e alimentos) e biológicos (determinados vírus, bactérias e parasitas), além do estilo de vida adotado por cada indivíduo. Proto-oncogenessão responsáveis pela divisão e crescimento celular em condições normais, podem se tornar oncogenes durante a mutação genética. Além disso, a falta de genes supressores de tumores desencadeia a divisão de células descontroladas (SILVA; MATTOS, 2011; HASSANNPOUR; DEGHANI, 2017).

A tumorigênese tem sido considerada como um mecanismo autônomo da célula desencadeado pela acumulação de mutações capazes de conferir uma vantagem de


crescimento às células transformadas e a capacidade de invadir tecidos circundantes e eventualmente promover a metástase. A denominação do câncer é feita de acordo com o tipo celular de origem, o termo carcinoma é utilizado se o câncer se iniciar a partir de células epiteliais, sarcoma caso sua origem seja de linhagem celular mesodérmica, linfoma se a origem for células do sistema imunológico e, por fim, o termo leucemia é utilizado se o câncer for originado de células da medula óssea (SULTANA, 2014; GANDELLINI et al., 2015).

No Brasil, os registros de câncer de base populacional, em conjunto com os registros hospitalares e com o sistema de informação sobre mortalidade do DataSUS (Departamento de Informática do Sistema Único de Saúde), formam o eixo estruturante para a vigilância e desenvolvimento de pesquisas sobre câncer, gerando condições necessárias para o planejamento e avaliação das ações de prevenção e controle do câncer. No ano de 2016, estimou-se 5.440 novos casos de câncer do Sistema Nervoso Central (SNC) em homens e 4.830 em mulheres. Esses valores correspondem a um risco estimado de 5,50 novos casos a cada 100 mil homens e 4,68 para cada 100 mil mulheres. Sem considerar os tumores de pele não melanoma, o câncer do SNC em homens é o oitavo mais frequente nas Regiões Sul e Nordeste, ocupa a décima posição nas Regiões Centro-Oeste e Norte, e na Região Sudeste é o 11º mais frequente. Para as mulheres, é o sexto mais frequente na Região Sul, e oitavo mais frequente na Região Centro-Oeste, já na Região Norte, ocupa a décima posição. Enquanto, nas Regiões Sudeste e Nordeste é o 11º (BRASIL, 2015).

## 1.2 GLIOBLASTOMAS

As células gliais (glial radial, astrócitos, endotélio) são células não neuronais que desempenham funções essenciais para a homeostase do SNC (figura 1), incluindo manutenção dos níveis iônicos do meio extracelular, tendo um papel crítico no metabolismo dos neurotransmissores, participação na formação da barreira hematoencefálica, secreção de fatores tróficos essenciais para a sobrevivência e diferenciação dos neurônios, direcionamento de axônios e formação e funcionamento das sinapses. Também estão envolvidos na regulação do fluxo sanguíneo cerebral e do acoplamento neurovascular, bem como no auxílio na defesa imune, por meio da síntese e secreção de diversas citocinas inflamatórias. Além disso, essas células têm grande impacto no controle energético cerebral, em razão do fornecimento de energia e metabólitos (FURNARI et al., 2007; GOMES; TORTELLI; DINIZ, 2013).

**Figura 1 – Células Gliais**



Fonte: FURNARI et al., 2007.


Os tumores cerebrais adultos de origem glial são divididos em astrocitomas, oligodendrogliomas e oligoastrocitomas com base em várias características histopatológicas chave. Além disso, esses tumores são classificados clinicamente como astrocitoma de classe I (pilocítico), astrocitoma grau II (difuso) da Organização Mundial de Saúde (OMS) benigno, astrocitoma maligno da OMS III (anaplásico) e astrocitoma de grau IV (glioblastoma), a forma mais maligna. Astrocitomas difusos de baixa qualidade seguem cursos clínicos longos se detectados precocemente; no entanto, os gliomas mais graves de Grau III carregam uma sobrevivência de cinco anos para 29,4% dos pacientes, e os glioblastomas carregam uma sobrevivência de cinco anos para apenas 3,4% dos casos (NOCH; KHALILI, 2009; JUNG et al., 2013).

O glioblastoma é um tumor maligno com baixa taxa de sobrevivência. É um tumor em rápido crescimento e tem uma alta taxa de rotatividade celular. O tumor supera sua necessidade metabólica por neovascularização, porém, a neovascularização não consegue acompanhar o rápido crescimento do tumor, ocasionando focos de necrose, que podem se unir e formar uma grande área de necrose central. Isso ocorre porque os vasos patológicos não possuem uma barreira hematoencefálica adequada e estão associados a um certo grau de vazamento capilar. O tumor interage com tecido cerebral adjacente, causando edema relativamente extenso (METWALI; ELHAKIM, 2017).

A necrose é uma característica marcante do glioblastoma em mais de 85% dos casos. O seu crescimento é fisicamente restringido pelo crânio e para superar esse desafio, ocorre aumento da liberação de glutamato que ocasionando a morte excitotóxica aos neurônios circundantes (figura 2). O mecanismo de necrose no glioblastoma começa

com a depleção aguda de ATP celular como resultado do colapso da cadeia de transporte de elétrons e subsequente diminuição da fosforilação oxidativa. Com essa diminuição canais e bombas iônicas dependentes de ATP começam a falhar, o que inicia um aumento maciço do volume celular através do influxo de  $\text{Na}^+$ ,  $\text{Ca}^{2+}$  e diminuição do efluxo  $\text{K}^+$ . À medida que a membrana celular se rompe, os conteúdos da célula são liberados para o espaço extracelular e o estágio final de necrose envolve a ativação de proteases e uma resposta inflamatória localizada (SONTHEIMER, 2008; NOCH; KHALILI, 2009).

**Figura 2** – Mecanismo de necrose por excitotoxicidade glutamatérgica em glioblastoma.



Fonte: SONTHEIMER, 2008.

A decisão cirúrgica para o manejo de tumores com edema perifocal, que corresponde a maioria dos casos de glioblastomas, é direta e implica em biópsia tumoral quando possível. O exame histopatológico fornece ao médico um diagnóstico seguro com a possibilidade de uma maior análise imuno-histoquímica, que pode determinar o gerenciamento quimioterapêutico adicional e também determinar o prognóstico (METWALI; ELHAKIM, 2017).

### 1.3 PLANEJAMENTO E DESENVOLVIMENTO DE FÁRMACOS ANTINEOPLÁSICAS

Estudos visando o desenvolvimento de novos fármacos anticancerígenos tem aumentado, sendo o objetivo primordial desenvolver tratamentos mais efetivos e seletivos, visando à descoberta de novas estratégias que impeçam o avanço da doença, possibilitando um melhor prognóstico. Os significativos avanços na biologia do câncer, possibilitaram direcionar as buscas por moléculas que atuem com mecanismos

específicos para cada tipo de enfermidade, como inibição da polimerização da tubulina, atuação no DNA, bloqueadores enzimáticos ou de microtúbulos celulares (BRANDÃO et al., 2010).

Métodos toxicológicos *in vitro* tornam-se uma opção na triagem em busca de novas moléculas que possuam efeitos citotóxicos em linhagens neoplásicas, além de diminuir custos, obter respostas rápidas e colaborar com o princípio dos 3R's (reduction, refinement e replacement). Dentre as vantagens desses métodos estão delimitação de variáveis analisadas, maior facilidade na obtenção de dados significativos, redução no período dos testes, possibilita maior número de repetições, além disso, requer menor quantidade da substância em análise (HARTUNG; DASTON, 2009; BEDNARCZUK et al., 2010).

Um dos ensaios mais utilizados é o testes do MTT (brometo de 3-(4,5-dimetiliazol-2-il) -2,5-difeniltetrazólio), onde células viáveis acumulam o sal amarelo MTT por endocitose e são capazes de transformá-lo em cristais de formazan. A redução do anel tetrazólico deste sal resulta na formação de cristais formazan de cor azul-purpura que se acumulam em compartimentos endossomais e/ou lisossomais. (FEKRAZAD et al., 2017).

A integração de estratégias computacionais e experimentais tem sido de grande valor na identificação e desenvolvimento de novos compostos promissores. Amplamente utilizado no design de fármacos modernos, os métodos de docking molecular exploram as conformações de ligantes adotadas nos locais de ligação aos alvos macromoleculares. Esta abordagem também estima a energia livre de ligação ligante-receptor, avaliando fenômenos críticos envolvidos no processo de reconhecimento intermolecular (FERREIRA et al., 2015).

Os avanços nos anos tornaram viável o uso de algoritmos intensivos em computação para triagem virtual de alta produtividade e triagem virtual inversa de interações moleculares. A primeira envolve o acoplamento de muitos ligantes contra um ou alguns receptores, enquanto que o segundo acopla muitos receptores contra um ou alguns ligantes. Uma combinação de algoritmos de identificação de poses e pontuação constituem a base dos mecanismos dos estudos de ancoragem. Os resultados de ancoragem molecular são avaliados por inspeção visual das poses do ligante ou quantitativamente usando um algoritmo de pontuação (JACOB; ANDERSEN; MCDOUGAL, 2012).

O software GOLD é um dos programas mais usados e adequados em vários estudos de ancoragem. É um programa flexível baseado em algoritmos genéticos para explorar a gama completa de flexibilidade conformacional do ligante com flexibilidade

parcial da proteína e satisfaz o requisito fundamental de que o ligante deve deslocar a água na ligação (JONES, 1997).

#### 1.4 TOPOISOMERASE-II- $\alpha$ E TUBULINA

As topoisomerasas são enzimas nucleares ubíquas que controlam o enovelamento do DNA. São essenciais durante a transcrição e a replicação e os inibidores da topoisomerase estão entre os fármacos anticancerígenos e antibacterianos mais eficazes e mais comumente usados, que se ligam e bloqueiam a atividade dessa enzima, seguindo-se a inibição da replicação do DNA (POMMIER, 2013; SADEGHI, 2015).

Os inibidores de Topoisomerase são eficazes, mas com limitada seletividade ao tumor. Seus efeitos colaterais e toxicidades limitantes da dose são devidas a toxicidade a células saudáveis, que, como as células cancerosas, precisam da topoisomerasas para manutenção de sua homeostase. Os fármacos anticancerígenos topoisomerase II alfa (TOP2A) minimiza os efeitos adversos de drogas não seletivas, como a leucemia mieloide aguda relacionada à terapia (T-AML) e cardiotoxicidade (RHAO, 2013, POMIER 2013).

Os microtúbulos são também importante alvo para terapias contra o câncer devido ao seu importante papel no citoesqueleto em células eucarióticas e suas funções na manutenção da forma celular, tráfico de proteínas, sinalização e segregação de cromossomos durante a mitose. Os agentes de segmentação de microtúbulos funcionam interferindo na dinâmica de controle do equilíbrio entre a montagem e desmontagem dos microtúbulos. Foram identificados quatro principais locais de ligação para esses agentes: o sítio do taxano e o sítio do laulimalídeo / peloreto A, para agentes de estabilização. E o local da vinca e da colchicina para agentes desestabilizadores de microtúbulos (DA et al., 2013; LI et al., 2017).


Os microtúbulos são importantes reguladores das células endoteliais, por isso há interesse em desenvolver agentes inibidores do sítio da colchicina para o tratamento do câncer, recentemente intensificou-se estudos com foco em inibição da angiogênese (prevenção da formação de novos vasos sanguíneos) e agentes disruptores vasculares (eliminação da vasculatura existente). Em particular, a família combretastatina estão progredindo através de ensaios clínicos para esse fim. Espera-se que novos agentes para o sítio da colchicina possam contornar a superexpressão da tuberculina  $\beta$ III que compromete o uso clínico de taxanos e alcalóides da vinca (DA et al., 2013).

## 1.5 CHALCONAS

A maioria dos fármacos anticâncer introduzidas na terapêutica nas últimas décadas são originados ou derivados de produtos naturais (vimcristina, vindesina, paclitaxel), mostrando que essa fonte é muito importante nos estudos de desenvolvimento de novos medicamentos (BRANDÃO et al., 2010; LEITE; OLIVEIRA-FILHO, 2014).

Uma das classes mais estudadas de moléculas são as chalconas, que são cetonas  $\alpha,\beta$ -insaturadas, com dois anéis aromáticos (figura - 2). O esqueleto molecular é caracterizado por porções de anéis aromáticos conectadas através de ponte de três carbonos com um grupo cetocarbonilo e uma  $\alpha,\beta$ -insaturação. As chalconas são uma classe de flavonoides intermediários que apresenta importância farmacológica devido à sua presença em muitos compostos farmacêuticos (ARRUDA et al., 2016; CUSTODIO et al., 2017).

**Figura 3** – Estrutura Fundamental das Chalconas



Fonte: CUSTODIO et al., 2017.

As chalconas e os derivados de chalconas são muitas vezes obtidos a partir de fontes naturais ou sintéticas. Devido à sua estrutura, estas moléculas são muito versáteis, pois podem conter diferentes anéis aromáticos, fundidos ou não, com heteroátomos na sua estrutura e diferentes substituintes. A reação de Claisen-Schmidt, que é a condensação de uma cetona aromática com um aldeído aromático na presença de um catalisador, é o método mais utilizado para a síntese de chalconas (RITTER et al., 2015; CUSTODIO et al., 2017).

Muitos estudos foram realizados com esta classe e uma gama de atividades foram relatadas, tais como anti-inflamatório, antifúngico, antibacteriano, leishmanicida, antiparasitário, antituberculoso, atividade antioxidante, antiulcerosos, citotóxicos, inseticidas e anticancerígenos (CUSTODIO et al., 2017).

### 2.1 OBJETIVO GERAL

Avaliar a atividade antineoplásica de chalconas sintéticas utilizando modelos de glioblastomas *in vitro* e docking molecular.

### 2.2 OBJETIVOS ESPECIFICOS

- a) Investigar a ação citotóxica de chalconas sintéticas frente a linhagem sadia AN27;
- b) Investigar a atividade citotóxica de chalconas sintéticas em linhagens de glioblastoma (U87 e AHOL1);
- c) Estudo das interações entre chalconas sintéticas e o alvo Topoisomerase-II- $\alpha$ ;
- d) Estudo das interações entre chalconas sintéticas e o alvo tubulina;

*Submetido para publicação no European Journal of Medicinal Chemistry.*

**EVALUATION OF ANTINEOPLASTIC ACTIVITY OF SYNTHETIC CHALCONES USING  
IN VITRO GLIOBLASTOMA AND MOLECULAR DOCKING MODELS FOR  
TOPOISOMERASE-II- $\alpha$  AND TUBULIN**

Raimundo de Almeida Mira Neto<sup>a\*</sup>, Shyanne Vanessa Correa Henriques<sup>a</sup>, Cleydson Breno Rodrigues dos Santos<sup>b</sup>, Leonardo Bruno Federico<sup>c</sup>, Edivaldo Herculano Corrêa de Oliveira<sup>d</sup>, Michel Platini Caldas de Souza<sup>d</sup>, Patrícia Natália B. da Silva<sup>e</sup>, Irlon M. Ferreira<sup>e</sup>, Madson Ralide Fonseca Gomes<sup>\*a</sup>.

Post graduate program in Pharmaceutical Sciences. Clinical Laboratory. Federal University of Amapá, Macapá, Brazil.<sup>a</sup>

Modeling and Chemistry Laboratory, Federal University of Amapá, Macapá, Brazil.<sup>b</sup>

Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of Sao Paulo, Ribeirão Preto, Brazil.<sup>c</sup>

Laboratory of Tissue Culture and Cytogenetics, SAMAM, Evandro Chagas Institute, Ananindeua, Para, Brazil.<sup>d</sup>

Group Biocatalysis and Biotransformation Group in Organic Chemistry, Collegiate of Chemistry Federal University of Amapá, Macapá, Brazil.<sup>e</sup>

## ABSTRACT

Glioblastoma is a malignant tumor with a low patient survival rate and its incidence is increasing. The number of studies aiming at developing new anticancer drugs have increased, and predicting the mode of anchoring promising molecules to the site of interest is paramount in rational drug design. This study evaluated the antineoplastic activity of synthetic chalcones using in vitro glioblastoma models and proposed molecular docking at the site of these molecules' action. The MTT assay showed that AHOL1 and U87 cellular viability was significantly reduced compared to healthy AN27 cells when exposed to chalcones ( $p < 0.0001$ ). Comparative analysis of molecular interactions with the topoisomerase II- $\alpha$  target identified interactions with serine (SER148–149) and isoleucine (ILE125). Interaction with the serine amino acid was present in both the most promising and the reference binder docking, suggesting its importance inhibiting cell growth. Comparative analysis between the reference ligands and the molecules in this study showed that the amino acid LYS 352 present in all fittings, suggesting that this is the main amino acid for interaction with tubulin. It was also observed that the absence of interaction with the amino acid CYS 241 causes a reduction in the Gold score. The results obtained in molecular docking are consistent with those observed in MTT, suggesting that the molecules under study have antineoplastic potential in glioblastoma.

**KEY WORDS:** chalconas; cytotoxicity; molecular docking; topoisomerase II alpha; tubulin;

### 1. Introduction

Cancer is a disease that is caused by genomic changes, especially somatic cell mutations. Cancer development is driven by the accumulation of changes that affect genomic structure and function. These changes are often acquired as a result of exposure to multiple carcinogenic agents, affecting the functioning of the proteins encoded by the

altered genes and the whole circuit that controls cell growth, replicative potential, survival, and stress response. These processes include oxidative damage, errors in the action of polymerases and recombinases, and reduction and chromosomal rearrangement [1-4]. Adult brain tumors of glial origin are divided into astrocytomas, oligodendrogliomas, and oligoastrocytomas based on several key histopathological features. Diffuse, low-grade astrocytomas follow a long clinical course if detected early; however, the more severe Grade III gliomas carry a 5-year survival of 29.4%, and glioblastomas carry a 5-year survival of only 3.4% [5,6].

Glioblastoma is a malignant tumor with low survival rate, and it has rapid growth and a high turnover rate. The tumor overcomes its metabolic need for neovascularization, but neovascularization fails to keep up with its rapid growth, causing foci of necrosis that can unite and form a large area of central necrosis. This is because pathological vessels do not have an adequate blood-brain barrier and are associated with capillary leakage. The tumor interacts with adjacent brain tissue, causing relatively extensive edema [7,8].

The number of studies aimed at the development of new anticancer drugs have been increasing, with the objective of developing more effective and selective treatments. Significant advances in cancer biology have made it possible to direct the search for molecules that act with specific mechanisms, such as inhibition of tubulin (TUB) polymerization, DNA activation, enzymatic blockers, or cellular microtubules [9]. In vitro and in silico methods have become a valuable option to screen for new molecules. The advantages of these methods are the delimitation of the analyzed variables, reduced test duration, greater number of repetitions and require less quantity of the substance under analysis [10-12].

Predicting the mode of anchoring small molecules to macromolecules that have a known three-dimensional structure is a main problem in the rational design of drugs. Sequencing the human genome also generated an increase in the number of new

therapeutic targets for research. Additionally, high-throughput crystallographic and nuclear magnetic resonance methods were developed and these contributed to a more detailed understanding of protein and protein-ligand complex atomic structure, and molecular coupling studies are used as a tool to develop new drugs [13-15].

Therefore, the aim of this study is to evaluate the antineoplastic activity of synthetic chalcones using in vitro glioblastoma models and to use molecular docking to suggest the mechanism of action for these molecules.

## 2. Materials and methods

### 2.1 Chemicals

Acetophenone 1a (99%), 4-hydroxiacetophenone 1b (99%), cyclohexanone 1c (99%), benzaldehyde 2a (99%), 3-bromobenzaldehyde 2c (99%), 4-methylbenzaldehyde 2b (99%) and 3-nitrobenzaldehyde 2e (99%) were purchased from Sigma-Aldrich, 4-anisaldehyde 2b (98%) from Vetec and sodium hydroxide (97%) and hydrochloric acid (37%) from Quemis.

### 2.2 Spectroscopic Analysis

For gas chromatography–mass spectrometry, a Shimadzu GC2010 Plus gas chromatography system coupled to a mass-selective detector (Shimadzu MS2010 Plus) in electron ionization mode (70 eV) was used. <sup>1</sup>H NMR spectra were recorded on an Agilent Technologies 500/54 Premium Shielded or Agilent Technologies 400/54 Premium Shielded spectrometer, with CDCl<sub>3</sub> as the solvent and TMS as the internal standard unless otherwise noted. The chemical shifts are given in ppm and coupling constants (*J*) in Hz.

### 2.3 Preparation of the chalcones 3a–e

In two-necked round-bottomed flasks, mixtures of one of the ketones 1a–c (10 mmol), benzaldehydes 2a–e (11 mmol) and anhydrous EtOH (50 mL) were prepared. Each solution was stirred at room temperature for 5 min, after which 5 mL of NaOH was added ( $6 \text{ molL}^{-1}$ ). The reaction was stirred at room temperature for 12 h, and then stopped by adding HCl (5 mL, 10%), yielding a yellow precipitate. The precipitate was filtered off and recrystallized from EtOH. The products (3a–f) were obtained in good yields and identified by comparing spectroscopic data ( $^1\text{H NMR}$ , GC–MS) with data in the literature Ferreira et. al. 2014. [16]





Figure 1 - Molecular structure of the synthesized chalcones

## 2.4 Spectral Data


### *(E)*-1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-one (3a)



3a


C<sub>15</sub>H<sub>12</sub>O<sub>2</sub>; 224 g.mol<sup>-1</sup>; yellow solid; mp = 192 °C; <sup>1</sup>H NMR (500 MHz, Chloroform) δ 8.23 (d, *J* = 15.2 Hz, 1H), 7.63 – 7.54 (m, 4H), 7.45 – 7.38 (m, 3H), 7.34 (td, *J* = 7.5, 1.4 Hz, 1H), 7.01 (td, *J* = 7.5, 1.4 Hz, 1H), 6.94 (dd, *J* = 7.5, 1.4 Hz, 1H), 3.97 (s, 1H).

### *(E)*-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one (3b)




C<sub>16</sub>H<sub>14</sub>O<sub>2</sub>; 238 g.mol<sup>-1</sup>; yellow solid; mp = 77 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm) 3.90 (s, 3H), 6.97-7.01 (m, 2H), 7.39-7.44 (m, 3H), 7.55 (d, *J* = 15 Hz, 1H), 7.62-7.67 (m, 2H), 7.83-7.81 (d, *J* = 15.6 Hz, 1H); MS (EI, 70 eV) *m/z* = 238, 223, 161, 133, 108, 77.

### *(E)*-3-(3-bromophenyl)-1-phenylprop-2-en-1-one (3c)




C<sub>15</sub>H<sub>11</sub>BrO; 287 g.mol<sup>-1</sup>; yellow solid; mp = 154 °C; <sup>1</sup>H NMR (500 MHz, Chloroform) δ 8.24 (d, *J* = 15.0 Hz, 1H), 7.83 – 7.74 (m, 3H), 7.59 (ddd, *J* = 9.8, 8.3, 7.5 Hz, 2H), 7.56 – 7.40 (m, 4H), 7.31 (t, *J* = 7.4 Hz, 1H).

*(E)*-2-benzylidenecyclohexan-1-one (*3d*)




C<sub>14</sub>H<sub>16</sub>O; 200 g.mol<sup>-1</sup>; yellow solid; mp= 192 °C; <sup>1</sup>H NMR (500 MHz, Chloroform) δ 7.50 (dt, *J* = 4.4, 2.3 Hz, 1H), 7.43 – 7.34 (m, 2H), 2.95 (t, *J* = 6.1 Hz, 1H), 2.40 (td, *J* = 5.5, 0.7 Hz, 1H), 1.62 (dp, *J* = 36.1, 5.5 Hz, 2H).

*(E)*-1-phenyl-3-(*p*-tolyl)prop-2-en-1-one (*3e*)



C<sub>16</sub>H<sub>14</sub>O; 222 g.mol<sup>-1</sup>; yellow solid; mp = 107 °C; <sup>1</sup>H NMR (500 MHz, Chloroform) δ 8.22 (d, *J* = 15.2 Hz, 1H), 7.77 (dd, *J* = 7.5, 1.4 Hz, 2H), 7.59 (d, *J* = 15.2 Hz, 1H), 7.57 – 7.40 (m, 5H), 7.29 (d, *J* = 7.5 Hz, 2H), 2.36 (s, 3H).

*(E)*-3-(3-nitrophenyl)-1-phenylprop-2-en-1-one (*3f*)



C<sub>15</sub>H<sub>11</sub>NO<sub>2</sub>; 253 g.mol<sup>-1</sup>; yellow solid; mp = 108-109 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm) 7.55 (t, *J* = 7.5 Hz, 1H), 7.63 (dd, *J* = 7.7 Hz and 3.2 Hz, 1H), 7.67 (d, *J* = 15.6 Hz, 1H), 7.85 (d, *J* = 15.6 Hz, 1H), 7.94 (d, *J* = 7.7 Hz, 1H), 8.0 (s, 2H); MS (EI, 70 eV) *m/z* = 253, 236, 206, 178, 105, 77.

## 2.5 Determination of cytotoxicity using the MTT assay

AN27, AHOL1, and U87 cells were seeded at  $0.7 \times 10^5$  cells/mL in 96-well plates. After 24 h, the tested compounds were added and incubated for 72 h at 37°C in a humid atmosphere containing 5% CO<sub>2</sub>. After incubation, the medium was changed to a fresh medium containing 150 µL MTT (0.5 mg/mL) and incubated for 3 h. The plates were centrifuged again, the supernatants discarded, and the precipitate resuspended in 150 µL DMSO. To quantify Formazan using viable cells, the absorbances were read at 595 nm. A negative control was used when 0.5% DMSO medium (solvent) was added to the cells. Cell viability was expressed as the percentage of control cells and was calculated using the following equation:  $\% CV = A_t / A_c \times 100$  equation, where % CV is cell viability in percent,  $A_t$  and  $A_c$  are the absorbances of treated and untreated cells, respectively, after subtracting the absorbance from MTT [17,18].

## 2.6 Molecular docking

Topoisomerase II alpha (TOPIIA) and tubulina (TUB) structures obtained using X-ray diffraction were downloaded from Protein Data Bank (PDB) with PDB codes 1ZXM (*Homo sapiens*) and 4O2B (*Rattus norvegicus*, *Bos taurus*, and *Gallus gallus*) with resolution of 1.87 and 2.3 Å, respectively [19-20]. The ligands used in the molecular docking study were six synthetic chalcones designed and pre-optimized in MM+ in the ACD / ChemSketch program and optimized in the HyperChem program using the semi-empirical AM1 method [21].

The protein/linker complex obtained in the PDB was inserted into the Gold program to validate the method, with **the** Phosphoaminophosphonic Acid-Adenylate Ester (ANP) structure bound to TOPIIA (*H. sapiens*, PDB 1ZXM) and the TUB bound colchicine structure (*R. norvegicus*, PDB 402B) and these were used as standard parameters by the genetic algorithm [22,23]. Docking studies for TOPIIA and TUB that targeted the

complexed test molecules were performed and visualization of the distances from the ligand to target interactions were performed using the Discovery Studio v17.2.0.16349 software.

## 2.7 Statistical analysis

The results were expressed as the mean and standard deviation, and data were analyzed using a two-way ANOVA, followed by Bonferroni's test. The inhibitory concentration to 50% of the sample ( $IC_{50}$ ) was calculated using sigmoidal regression in a dose-dependent curve. The 95% confidence interval and  $p < 0.05$  were considered in all analyzes, using Graph Pad Prism 5.0 software.

## 3. Results and discussion

### 3.1. Cytotoxicity of MTT assay

The MTT test was the first widely accepted method to evaluate cytotoxicity and cell viability. The assay consists of the colorimetric determination performed on microtiter plates, where the absorbance measurements were obtained at the end of the test. Its main assumption depends on tetrazolium as an indicator of the potential for intracellular reduction, which, in turn, assesses overall cellular status and viability [24].

The strains AHOL1 and U87 were selected to evaluate the cytotoxic effect in neoplastic glioblastoma lines, compared to the AN27 line of healthy human fibroblasts. Cell viability was expressed as the percentage of viable cells relative to control. The main assumption depends on tetrazolium salt as an indicator of the intracellular reduction potential, which assesses the cell status and global viability. The enzymatic reduction of tetrazolium by cytosolic dehydrogenases and reducing agents results in the formation of water insoluble violet blue formazan products [24].

Chalcones (1,3-diaryl-2-propen-1-one) are natural intermediates of flavonoid compounds. The core structure of chalcones consists of two aromatic rings where are connected by a three carbon  $\alpha$ ,  $\beta$ -unsaturated carbonyl bridge. They are important compounds that show biological activity and have anticancer potential [25].

The MTT assay results showed that AHOL1 and U87 cells had reduced cell viability when exposed to molecule 3a, with an IC<sub>50</sub> of 56.97 mg/mL and 67.96 mg/mL, respectively, and at a concentration of 75 mg/mL at ( $p < 0.0001$ ) compared to the AN27 lineage that did not show reduced viability (Figure 2A). For the second molecule (3b), viability reduction was also observed in AHOL1, with an IC<sub>50</sub> of 36.32 mg/mL and U87 with an IC<sub>50</sub> of 50.07 mg/mL. The AN27 line was not changed, showing a statistical difference compared to the other strains at concentrations of 50, 75, and 100 mg/mL ( $p < 0.0001$ , Figure 2B).

Molecule 3c also promoted a reduction in the cellular viability of AHOL1 and U87, with an IC<sub>50</sub> of 33.95 mg/mL and 50.15 mg/mL, respectively, which was significant compared with AN27 ( $p < 0.001$ ) at concentrations of 25, 50–75, and 100 mg/mL (Figure 2C). Molecule 3e reduced viability, with an IC<sub>50</sub> 27.43 mg/mL and 54.23 mg/mL for the AHOL1 and U87 lines, respectively, which was statistically significant at concentrations of 50, 75, and 100 mg/mL compared to strain AN27 (Figure 2D).

The MTT showed that molecule 3f was effective in reducing the cell viability of the three strains studied at concentrations above 25 mg/mL, and there was only a significant difference at concentrations of 7.5 and 10 mg/mL ( $p < 0.0001$ ) between AN27 and the glioblastoma lines AHOL1 and U87 (Figure 2F). The molecule 3d was not effective to reduce the cell viability of the studied strains (figure 2D).




Figure 2 - Cell viability analysis of AN27, AHOL1 and U87 by the MTT assay. (A) 3a. (B) 3b. (C) 3c. (D) 3d. (E) 3e. (F) 3f. Two-way ANOVA; post-test of Bonferroni. \*\*\*  $p < 0.0001$ .

### 3.2. Molecular docking study

To propose a mechanism of action for chalcones that had an effect on the reduction of cell viability using MMT, a molecular docking study was performed for TOPIIA and TUB targets, using the Gold software, which is one of the most frequently used and suitable programs for anchorage studies. It is a flexible program based on genetic algorithms to explore the full range of binder conformational flexibility with partial flexibility of the protein and it meets the fundamental requirement that the binder should displace the water during binding [13].

To validate the anchoring method, ANP and colchicine structures with crystallographic information were subjected to redocking until the results obtained by the software were similar to crystallographic information. Comparison between ANP and colchicine (green) crystallographic ligands and those resulting from redocking (red) are shown in Figure 4. The RMSD values obtained were 1.0706 and 0.3313, respectively, which is within the recommended range, as described below [26]. Thus, redocking reproduced the experimental linking modes, validating the ligand docking.




Figure 3 - Comparison between the crystallographic binder (green) and the best conformation obtained by molecular docking (red). (A) ANP and (B) Colchicine.

After the method was validated, molecular docking was used to predict the affinity of five synthetic chalcones with the targets under study. The docking method identified a conformation that allowed interaction with the ANP active sites (PDB 1ZXM) that occur between amino acid residues 87–95, 137–143, and 162–169 in the alpha helix, and between amino acid residues 116–125, 177–183, and 214–219 for the  $\beta$  leaf. The interaction sites for colchicine (PDB 402B) occur between amino acid residues 238–243 and 252–259 in the alpha helix, and between amino acid residues 135–137, 167–202, 314–318, 351–354, and 377–381 for the  $\beta$  sheet.

The redocking analysis for ANP identified hydrogen bonding with amino acids ASN 91, ASN 120, SER 148, ASN 163, TYR 165, GLY 166, and LYS 168. Pi-amide stacking

occurred at ALA 92, carbo-hydrogen bonding at ASN 95 and GLY 164, Pi-alkyl bonding was present at ILE 125, and acceptor and donor interaction occurred at SER 149 and ARG 162, respectively (Figure 4).




Figure 4 - Molecular redocking of ANP and interactions with Topoisomerase II- $\alpha$  residues

The redocking analysis for colchicine and tubulin revealed four Pi-alkyl interactions at CYS 241, LEU 255, ALA 316, and LYS 352. Additionally, two hydrogen-carbon bond-type interactions that occur at amino acids ASN 258 and VAL 315; an alkyl interaction at LEU 255; and a Pi-sulfur at the MET 259 inlet, totaling eight interactions with the molecular target (Figure 5).




Figure 5 - Colchicine molecular docking and 2D diagram of the interactions with Tubulin residues.

### 3.2.1. Molecular docking for topoisomerase II- $\alpha$

Topoisomerases are nuclear enzymes that control DNA folding and are essential during transcription and replication, and topoisomerase inhibitors are among the most

commonly used and effective anti-cancer and antibacterial drugs that bind and block the activity of that enzyme, followed by inhibition of DNA replication [27,28].

Analysis of doxorubicin (Figure 6) indicated the presence of three hydrogen bonds, two at ASN 91 and one at ASN 120; and two Pi-alkyl interactions at ILE 125, one at VAL 137, and two at ILE 141. There is also a hydrogen bond-carbon at SER 148, an alkyl interaction at ALA 167, and a donor-donor bond at LYS 168, totaling 11 interactions with the receptor.




Figure 6 - Molecular docking and 2D diagram of doxorubicin and Topoisomerase II- $\alpha$  binding pocket interactions

For molecule 3a, two interactions with the active site were identified: a hydrogen-carbon bond at SER 148 and a hydrogen interaction at SER 149. Molecule 3b also presented two target sites with a hydrophobic pi-alkyl at ILE 125, and a hydrogen bond at SER 149. Analysis of molecule 3c showed two interactions per carbon-hydrogen bond at SER 148 and SER 149, but in the amino acid SER 148, there was an unfavorable acceptor-acceptor interaction, a Pi-alkyl at PHE 142, and an alkyl interaction with the ILE 217 amino acid, totaling five interactions with the target (Figures 7 and 8).

Were seven interactions between molecule 3d and the target under study. Two Amide-Pi Stacked interactions in ASN 91 and ALA 92, two Pi-alkyl interactions in ILE 125 and PHE 142, two alkyl interactions in ILE 142 and ALA 157, and a carbon-hydrogen bond

in SER 149. Molecule 3e showed a carbon-hydrogen bond at the amino acid SER 148, and a hydrogen bond at SER 149, totaling two interactions with the molecular target (Figure 11). Molecule 3f analysis revealed two charge-load interactions in GLU 87, and four hydrogen bonds at ARG 162, ASN 163, TYR 165, and GLY 166, totaling six interactions with TOPIIA (Figures 7 and 8).

Comparative analysis of the molecular interactions with the target identified two repeated interactions in serine (SER148–149) and isoleucine (ILE125). The amino acid SER was present in the interactions of the ANP ligand with TOPIIA in doxorubicin and molecules of chalcones a,b, c, e, and f, suggesting its fundamental importance in the inhibitory effect on cell growth. Additionally, molecule 3f in the MTT test showed the lowest selectivity between healthy and neoplastic cells, suggesting the importance of the amino acid SER in selectivity for TOPIIA and neoplastic cells.

The drug doxorubicin targets TOPIIA and topoisomerase 2 beta (TOPIIB), and is associated with several adverse effects and cardiotoxicity. TOPII $\beta$  is present in most tissues, including tumors, and TOPII $\alpha$  is absent in cardiac tissue; thus, selective antineoplastic drugs for TOPIIA present more selectivity for tumoral tissue and lower cardiotoxicity [28].

Topoisomerase inhibitors are effective, but they have limited tumor selectivity. Their side effects and dose-limiting toxicities cause toxicity to healthy cells, which, like cancer cells, need topoisomerases to maintain their homeostasis. TOPIIA anticancer drugs minimize the adverse effects of non-selective drugs, such as therapy-related acute myeloid leukemia (T-AML) and cardiotoxicity [27,29].




Figure 7 - Molecular docking and interactions with Topoisomerase II- $\alpha$  residues. (A) 3a. (B) 3b. (C) 3c. (D) 3d. (E) 3e. (F) 3f.




Figure 8 - Molecular docking and interactions with Topoisomerase II- $\alpha$  residues. (A) 3a. (B) 3b. (C) 3c. (D) 3d. (E) 3e. (F) 3f.

Table 2 - Distances, types of interaction and gold score between binders and Topoisomera II alpha

Structure	Aminoacids	Distance (Å)	Interaction Type	Gold Score
<b>Phosphoaminophosphonic Acid-Adenylate Ester</b>	ASN 91	1.75	Hydrogen bond	76.2451
	ASN 91	2.41	Hydrogen bond	
	ALA 92	4.82	Amide-Pi stacked	
	ALA 92	5.30	Amide-Pi stacked	
	ASN 95	2.60	Hydrogen-carbon bond	
	ASN 120	2.69	Hydrogen bond	
	ILE 125	5.35	Pi-alkyl	
	SER 148	2.88	Hydrogen bond	
	SER 149	2.60	Acceptor-acceptor	
	ARG 162	2.65	Donor-donor	
	ASN 163	1.79	Hydrogen bond	
	GLY 164	2.94	Hydrogen-carbon bond	
	TYR 165	1.91	Hydrogen bond	
	GLY 166	1.74	Hydrogen bond	
LYS 168	2.10	Hydrogen bond		
Doxorubicina	ASN 91	2.14	Hydrogen bond	73.6892
	ASN 91	2.96	Hydrogen bond	
	ASN 120	2.01	Hydrogen bond	
	ILE 125	4.45	Pi-alkyl	
	ILE 125	4.96	Pi-alkyl	
	VAL137	5.00	Pi-alkyl	
	ILE 141	4.78	Pi-alkyl	
	ILE 141	5.01	Pi-alkyl	
	SER 148	2.43	Hydrogen-carbon bond	
	ALA 167	3.21	Alkyl	
LYS 168	2.62	Donor-Donor		
3a	SER 148	3.03	Hydrogen-carbon bond	52.7719
	SER 149	1.83	Hydrogen bond	
3b	ILE 125	5.17	Pi-alkyl hydrophobic	54.7246
	SER 149	1.80	Hydrogen bond	
3c	PHE 142	4.79	Pi-alkyl	54.9591
	SER 148	2.88	Unfavorable acceptor	
	SER 148	3.02	Hydrogen-carbon bond	
	SER 149	1.85	Hydrogen-carbon bond	
3d	ILE 217	4.92	Alkyl	42.7550
	ASN 91	4.87	Amide-Pi stacked	
	ALA 92	4.87	Amide-Pi stacked	
	ILE 125	5.31	Pi-alkyl	
	ILE 142	3.98	Alkyl	
	PHE 142	4.65	Pi-alkyl	
	SER 149	3.03	Hydrogen-carbon bond	
ALA 167	4.53	Alkyl		
3e	SER 148	3.07	Hydrogen-carbon bond	55.6680
	SER 149	4.90	Hydrogen bonding	

3f	GLU 87	4.73	Attractive Charge Unfavorable negative-negative	65.3370
	GLU 87	5.02		
	ARG 162	1.92	Hydrogen bond Hydrogen bond Hydrogen bond	
	ASN 163	2.04		
	TYR 165	2.02		
GLY 166	1.74	Hydrogen bond		

### 3.2.2. Molecular docking for tubulin

Microtubules are formed by the association of  $\alpha$ - and  $\beta$ -TUB heterodimers and serve as important components of the cytoskeleton in eukaryotic cells. They are important in the process of cell division, which makes them an important target for anticancer drugs. Target molecules in the microtubules can act by stabilizing or destabilizing, interfering in their dynamics, which can lead to mitotic block and cellular apoptosis. Four major binding sites for these agents have been identified: the taxane site and the laulimalide site for stabilizing agents, and the vinca and colchicine sites for microtubule destabilizing agents [30,31].

Doxorubicin analysis identified six interactions: four conventional bonds, three with LYS 254 and one with THR 353; one alkyl linkage with LYS 352; and one carbon-hydroxyl linkage with amino acid LYS 254 (Figure 9).




Figure 9 - Molecular docking and 2D diagram of doxorubicin and Tubulin binding pocket interactions

Molecule 3a showed five interactions with the tubulin site, three Pi-alkyl interactions with LEU 242, LEU 255, and LYS 352; a Pi-sulfur bond with MET 259; and a Pi-sigma bond with CYS 241. For molecule 3b, there were four Pi-alkyl interactions at ALA 316, LYS 352, LYS 352, and ALA 354; and a LYS 254 carbon-hydrogen bond, totaling five interactions. molecule 3c showed three PI-alkyl interactions at CYS 241, LEU 255, and LYS 352, two alkyl interactions at CYS 241 and ILE 318; an amide-Pi stacked ASN 258 interaction; and a Pi-sulfur bond MET 259 (Figures 10 and 11).

Three Pi-alkyl interactions were identified between molecule 3d and tubulin site in amino acids CYS 241, LEU 242 and LEU 255, and three alkyl interactions in LEU 255, ALA 316 and LYS 352. Analysis of the docking between molecule 3e and tubulin showed two alkyl interactions at CYS 241 and LEU 242, four Pi-alkyl bonds at MET 259, ALA 316, CYS 241, and LYS 352; a Pi-sigma bond at LEU 255; and a hydrogen bond at ASN 258. Molecule 3f showed two Pi-alkyl interactions at LYS 352, and two hydrogen bonds at ASN 258 and THR 353 (Figures 10 and 11).

Comparative analysis of the colchicine binder; doxorubicin, which is used clinically; and the molecules in this study identified the amino acid LYS 352 that was present at all interactions. This suggests that LYS 352 is the main amino acid that interacts with tubulin, and a second amino acid, CYS 241, may also be related to the reduction in the Gold score for interactions in which it is not present (doxorubicin, molecule 3b, and molecule 3f).

The microtubule plays an important role in fundamental cellular processes such as cell division; maintaining cellular integrity; and regulating motility, cell signaling, cellular secretion, and intracellular transport. Therefore, inhibition of microtubule function seems to be a strong approach for anticancer therapy. The unique feature of microtubule binding agents in contrast to other anticancer drug categories is their complexity and structural diversity, which offers many possibilities for scaffold optimization and design [32].




Figure 10 - Molecular docking and interactions with Tubulin residues. (A) 3a. (B) 3b. (C) 3c. (D) 3d. (E) 3e. (F) 3f.




Figure 11 - Diagram 2D of the interactions with Tubulin residues. (A) 3a. (B) 3b. (C) 3c. (D) 3d. (E) 3e. (F) 3f.

Table 3 - Distances, types of interaction and gold score between binders and TUB

Structure	Aminoacides	Distance (Å)	Interaction Type	Gold Score
Colchicina	CYS 241	5.50	Pi-Alkyl	80.0201
	LEU 255	4.21	Pi-Alkyl	
	LEU 255	5.00	Alkyl	
	ASN 258	3.04	Hydrogen-carbon bond	
	MET 259	5.23	Pi-Sulfur	
	VAL 315	2.49	Hydrogen-carbon bond	
	ALA 316	5.45	Pi-Alkyl	
LYS 352	4.20	Pi-Alkyl		
Doxorrubicina	LYS 254	1.47	Conventional Connection	54.0183
	LYS 254	2.78	Conventional	
	LYS 254	2.59	Hydrogen-carbon bond	
	LYS 254	2.81	Conventional	
	LYS 352	3.91	Alkyl	
	THR3 353	2.02	Conventional	
3a	CYS 241	2.80	Pi-Sigma	57.6683
	LEU 242	5.15	Pi-Alkyl	
	LEU 255	4.43	Pi-Alkyl	
	MET 259	5.13	Pi-Sulfur	
	LYS 352	4.65	Pi-Alkyl	
3b	LYS 254	2.63	Hydrogen-carbon bond	52.9918
	ALA 316	5.10	Pi-Alkyl	
	LYS 352	4.80	Pi-Alkyl	
	LYS 352	4.95	Pi-Alkyl	
	ALA 354	5.15	Pi-Alkyl	
3c	CYS 241	3.55	Alkyl	59.1093
	CYS 241	4.58	Pi-Alkyl	
	LEU 255	4.20	Pi-Alkyl	
	ASN 258	4.74	Amide-Pi stacked	
	MET 259	4.96	Pi-Sulfur	
	ILE 318	4.35	Alkyl	
	LYS 352	4.81	Pi-alkyl	
3d	CYS 241	4.45	Pi-Alkyl	43.5491
	LEU 242	4.81	Pi-Alkyl	
	LEU 255	5.35	Alkyl	
	LEU 255	4.35	Pi-Alkyl	
	ALA 316	4.56	Alkyl	
	LYS 352	5.40	Alkyl	
3e	CYS 241	4.10	Alkyl	59.2652
	CYS 241	4.91	Pi-alkyl	
	LEU 242	3.74	Alkyl	
	LEU 255	2.68	Pi-sigma	
	ASN 258	2.80	Hydrogen bond	
	MET 259	4.99	Pi-Alkyl	
	ALA 316	5.42	Pi-Alkyl	
	LYS 352	4.09	Pi-Alkyl	
3f	ASN 258	2.11	Hydrogen bond	53.8388
	LYS 352	4.87	Pi-Alkyl	
	LYS 352	4.97	Pi-Alkyl	
	THR 353	2.78	Pi-Donor Hydrogen bond	

## Conclusions

The antineoplastic activity of the six molecules was tested using AHOL1 and U87 glioblastoma lines, and a significant reduction of cell viability was observed compared with the AN27 healthy lineage. MTT results are consistent with predictions of molecular docking, where the molecules under analysis coupled to the target in a manner similar to doxorubicin and to the ligand that was coupled to the PDB. The amino acids serine (SER148–149) and isoleucine (ILE125) are potentially the most important for interaction with TOPIIA. For TUB, the amino acid LYS 352 is present in all the moieties, suggesting that LYS 352 is the main amino acid that interacts with the target. Additionally, the interactions occur mainly by alkylation of these amino acids. More studies are required.

## References

- [1]P. A. Silva, S. S. Riul, *Câncer De Mama: Fatores De Risco E Detecção Precoce*, Rev. Bras. Enfermagem,64 (6), (2011),1016-21.
- [2]L. Zhao, T. Sun, J. Pei, Q. Ouyang, Mutation-Induced Protein Interaction Kinetics Changes Affect Apoptotic Network Dynamic Properties And Facilitate Oncogenesis, *Proceedings Of The National Academy Of Sciences (Pnas)*. 13, (2015), E4046-4054.
- [3]J. F. S. Silva, I. E. Mattos, *Padrão De Distribuição Do Câncer Em Cidade Da Zona De Fronteira: Tendência Da Mortalidade Por Câncer Em Corumbá, Mato Grosso Do Sul, No Período 1980-2006\**, *Epidemiologia E Serviços De Saúde*, 20(1), (2011),65-74.
- [4]S. H. Hassanpour\*, M. Dehghani, *Review Of Cancer From Perspective Of Molecular*, *Journal Of Cancer Research And Practice*, 4, (2017), 127–129.
- [5]E. Noch, K. Khalili, *Molecular Mechanisms Of Necrosis In Glioblastoma: The Role Of Glutamate Excitotoxicity*, *Cancer Biology & Therapy*, 8, (2009), 1791–1797.
- [6]S. Liu, Y. Wang, K. Xu, Z. Wang, X. Fan, C. Zhang, S. Li, X. Qiu, T. Jlang. *Relationship Between Necrotic Patterns In Glioblastoma And Patient Survival: Fractal Dimension And Lacunarity Analyses Using Magnetic Resonance Imaging*, *Scientific Reports*, 7, (2017), 1-7. DOI:10.1038/S41598-017-08862-6.
- [7] H. Metwali, A. Elhakim, *Effects Of Different Therapeutic Approaches On Diagnosis Of Glioblastoma And Detection Of Its Recurrence*, *World Neurosurgery*, 109, (2018), 96-97.

- [8] D. Hambardzumyan, G. Bergers. Glioblastoma: Defining Tumor Niches. Trends Cancer. 1, (2015), 252-256. Doi:10.1016/J.Trecan.2015.10.009.
- [9] H.N. Brandão, J. P. David, R. D. Couto, J. A. P. Nascimento, J. M. David, Química E Farmacologia De Quimioterápicos Antineoplásicos Derivados De Plantas, Química Nova, 33, (2010), 1359-1369.
- [10] T. Hartung, G. Daston, Are In Vitro Tests Suitable For Regulatory Use?, Toxicological Sciences, 111(2), (2009), 233–237.
- [11] V. O. Bednarczuk, M. C. S. Verdam, M. D. Miguel, O.G. Miguel, Testes In Vitro E In Vivo Utilizados Na Triagem Toxicológica De Produtos Naturais, Visão Acadêmica, 11, (2010), 43-50.
- [12] M. Karthicka, M. Shanmugamb And V. Chidambaranathanc . Anti-Proliferation And Molecular Docking Study Of S-Triazinyl Uracil Hybrids , Der Pharmacia Sinica, 6, (2015), 28-38.
- [13] G. Jones, P. Willett, R. C. Glen, A. R. Leach, R. Taylor, Development And Validation Of A Genetic Algorithm For Flexible Docking, Journal Of Molecular Biology, 267, (1997), 727-748.
- [14] X. Y. Meng, Z. Hong-Xing, M. Mezei, E. M. Cui, Molecular Docking: A Powerful Approach For Structure-Based Drug Discovery. Current Computer-Aided Drug Design, 7, (2011), 146-157.
- [15] N. S. Pagadala, K. Syed, J. Tuszynski, Software For Molecular Docking: A Review, Biophysical Reviews, 9, (2017), 91–102.
- [16] I. M. Ferreira, L. C. Rocha, S. A. Yoshioka, M. Nitschke, A. H. Jeller, L. Pizzuti, M. H. R. Selegim, A. L. M. Porto. Chemoselective Reduction Of Chalcones By Whole Hyphae Of Marine Fungus *Penicillium citrinum* CBMAI 1186, Free And Immobilized On Biopolymers. Biocatalysis and Agricultural Biotechnology, 3, (2014), 358-364. doi.org/10.1016/j.bcab.2014.04.001
- [17] T. Mosmann. Rapid Colorimetric Assay For Cellular Growth And Survival: Application To Proliferation And Cytotoxicity Assays. J. Immunol. Methods, 65, (1983), 55-63.
- [18] N. Ashan, I. A. Siddique, S. Gupta, A. Surolia, A Routinely Used Protein Staining Dye Acts As An Inhibitor Of Wild Type And Mutant Alpha-Synuclein Aggregation And Modulator Of Neurotoxicity, European Journal Of Medicinal Chemistry, 143, (2018), 1174-1184.
- [19] H. Wei, A. J. Ruthenburg, S. K. Bechis, G. L. Verdine, Nucleotide-Dependent Domain Movement In The Atpase Domain Of A Human Type Iia Dna Topoisomerase, The Journal Of Biological Chemistry, 280, (2005), 37041-37047. Doi 10.1074/Jbc.M506520200
- [20] A. E. Prota, F. Danel, F. Bachmann, K. Bargsten, R. M. Buey, J. Pohlmann, S. Reinelt, H. Lane, M. O. Steinmetz. The Novel Microtubule-Destabilizing Drug Bal27862

Binds To The Colchicine Site Of Tubulin With Distinct Effects On Microtubule Organization, *Journal Of Molecular Biology*, (2014), 426. 1848-1860.

- [21] M. G. Birck, L. J. Campos, E. B. Melo. Estudo Computacional De 1h-Imidazol-2-Il-Pirimidina-4,6-Diaminas Para A Identificação De Potenciais Precursores De Novos Agentes Antimaláricos, (2016),39, 567-574.
- [22] E. C. Padilha, R. B.Serafim, D. Y. R. Sarmiento, C. F. Santos, C. B. R. Santos,C. H. T. P. Da Silva,New Ppara/Γ/Δ Optimal Activator Rationally Designed By Computational Methods. *J. Braz. Chem. Soc.*, 01, (2016),1-12.
- [23] A. L. E. Pereira, G. B. Dos Santos, M. S. F. Franco, L. B. Federico, C. H. T. P. Da Silva, C. B. R. Santos. Molecular Modeling And Statistical Analysis In The Design Of Derivatives Of Human Dipeptidyl Peptidase IV. *Journal Of Biomolecular Structure & Dynamics*, 35, (2017), 1-17.
- [24] R. Pascua-Maestro, M. Corraliza-Gomez, S. Diez-Hermano, C. Perez-Segurado, M. D. Ganfornina, D. Sanchez, The Mtt-Formazan Assay: Complementary Technical Approaches And In Vivo Validation In *Drosophila Larvae*, *Acta Histochemica*, (2018), 1-8. Doi:10.1016 /J.Acthis.2018.01.006.
- [25] H. Mirzaei, S. Emami, Recent Advances Of Cytotoxic Chalconoids Targeting Tubulin Polymerization: Synthesis And Biological Activity, *European Journal Of Medicinal Chemistry*, 121 (2016) 610-639.
- [26] K. E. Hevener, W. Zhao, D. M. Ball, K. Babaoglu, J. Qi, S. W. White, R. E. Lee, Validation Of Molecular Docking Programs For Virtual Screening Against Dihydropteroate Synthase. *Journal Of Chemical Information And Modeling*. 49, (2009), 444-460.
- [27] Y. Pommier, Drugging Topoisomerases: Lessons And Challenges, *Acs Chemical Biology*, 18, (2013), 82-95.
- [28] Sadeghi, M. Behmanesh, N. A. Chashmi, M. Sharifi, B. M. Soltani, 6-Methoxy Podophyllotoxin Induces Apoptosis Via Inhibition Of Tubb3 And Topiia Gene Expressions In 5637 And K562 Cancer Cell Lines, *Cell Journal(Yakhteh)*, 17, (2015), 502-509.
- [29] V. A. Rao, Iron Chelators With Topoisomerase-Inhibitory Activity And Their Anticancer Applications, *Antioxidants & Redox Signaling*, 18, (2013), 930-955.
- [30] C. Da, S. L. Mooberry, J. T. Gupton, G. E. Kellogg. How To Deal With Low-Resolution Target Structures: Using SAR, Ensemble Docking, Hydrophatic Analysis, And 3D-QSAR To Definitively Map The Aβ-Tubulin Colchicine Site, *Journal Of Medicinal Chemistry*, 56, (2013), 1-33. Doi:10.1021/Jm400954h.
- [31] W. Li, H. Sun, S. Xu, Z. Zhu, J. Xu. Tubulin Inhibitors Targeting The Colchicine Binding Site: A Perspective Of Privileged Structures. *Future Medicinal Chemistry*, 15, (2017), 1765-1794. Doi: 10.4155/Fmc-2017-0100

- [32] Khan, K. R. Garikapati, A. B. Shaik, V. K. K. Makani, A. Rahim, M. A. Shareef, V. G. Reddy, M. Pal-Bhadra, A. Kamal, Cg Kumar, Design, Synthesis And Biological Evaluation Of 1, 4-Dihydro Indeno[1,2-C] Pyrazole Linked Oxindole Analogues As Potential Anticancer Agents Targeting Tubulin And Inducing P53 Dependent Apoptosis, European Journal Of Medicinal Chemistry, (2018), 1-30, Doi:10.1016/J.Ejmech.2017.12.010.

## 5 CONSIDERAÇÕES FINAIS E PERSPECTIVAS

---

- Ocorreu redução da viabilidade celular das linhagens de glioblastoma AHOL1 e U87, expostas as chalconas, quando comparadas a viabilidade celular da linhagem AN27 saudável;
- Os resultados do MTT são consistentes com as previsões de docking molecular, onde as moléculas analisadas se acoplaram ao alvo de maneira similar à doxorrubicina e ao ligante que estava acoplado ao PDB;
- Os aminoácidos serina (SER148–149) e isoleucina (ILE125) são potencialmente os mais importantes para interação com TOPIIA;
- Para TUB, o aminoácido LYS 352 está presente em todas as frações, sugerindo que o LYS 352 é o principal aminoácido que interage com o alvo. Além disso, as interações ocorrem principalmente por alquilação desses aminoácidos. Mais estudos são necessários;
- São necessários estudos complementares *in silico* e *in vivo*, para garantir efetividade e segurança do uso dessas moléculas. Além de, melhor elucidar os mecanismos envolvidos na ação antineoplásica.

- ARRUDA, R. L.; PAZ, A. T. S.; BARA, M. T. F.; CÔRTEZ, M. V. C. B.; FILIPPI, M. C. C.; CONCEIÇÃO, E. C. An approach on phytoalexins: function, characterization and biosynthesis in plants of the family *Poaceae*. **Ciência Rural**, v.46, p.1206-1216, 2016.
- BEDNARCZUK, V.O.; VERDAM, M.C.S.; MIGUEL, M.D.; MIGUEL, O.G. Testes In Vitro E In Vivo Utilizados Na Triagem Toxicológica De Produtos Naturais. **Visão Acadêmica**, v. 11, p. 43-50, 2010.
- BRANDÃO, H. N.; DAVID, J. P.; COUTO, R. D.; NASCIMENTO, J. A. P.; David, J. M. Química e Farmacologia de Quimioterápicos Antineoplásicos Derivados de Plantas. **Química Nova**, v. 33, p. 1359-1369, 2010.
- BRASIL, Instituto Nacional de Câncer José Alencar Gomes da Silva. Coordenação de Prevenção e Vigilância. **Estimativa 2016: incidência de câncer no Brasil**. Rio de Janeiro: INCA, 2015.
- CUSTODIO, J. M. F.; Faria, E. C. M.; Sallum, L. O.; Duart, V. S.; Vaz, W. F.; Aquino, G. L. B.; Carvalho Junior, P. S.; Napolitano, H. B. The Influence of Methoxy and Ethoxy Groups on Supramolecular Arrangement of Two Methoxy-chalcones. **Journal of the Brazilian Chemical Society**. v. 1. p. 1-12, 2017.
- DA, C.; MOOBERRY, S. L.; GUPTON, J. T.; KELLOGG, G. E. How To Deal With Low-Resolution Target Structures: Using SAR, Ensemble Docking, Hydropathic Analysis, And 3D-QSAR To Definitively Map The A $\beta$ -Tubulin Colchicine Site. *Journal Of Medicinal Chemistry*, v 56. p. 1-33. 2013.
- FEKRAZAD, R.; AFZALI, M.; PASBAN-ALIABADI, H.; ESMAEILI-MAHANI, S.; AMINIZADEH, M.; MOSTAFAVI, A. Cytotoxic Effect of *Thymus caramanicus* Jalas on Human Oral Epidermoid Carcinoma KB Cells. **Brazilian Dental Journal**, v. 28, p. 72-77, 2017.
- FERREIRA, I. M.; ROCHA, L. C.; YOSHIOKA, S. A.; NITSCHKE, M.; JELLER, A. H.; PIZZUTI, L.; SELEGHIM, M. H. R.; PORTO, A. L. M. Chemoselective Reduction Of Chalcones By Whole Hyphae Of Marine Fungus *Penicillium citrinum* CBMAI 1186, Free And Immobilized On Biopolymers. **Biocatalysis and Agricultural Biotechnology**. V. 3.p. 1-20, 2015.
- FURNARI, F. B.; FENTON, T.; BACHOO, R. M.; MUKASA, A.; STOMMEL, J. M.; STEGH, A.; HAHN, W. C.; LIGON, K. L.; LOUIS, D. N.; BRENNAN, C.; CHIN, L.; DEPINHO, R. A.; CAVENEE, W. K. Malignant astrocytic glioma: genetics,biology, and paths to treatment. **GENES & DEVELOPMENT**, v. 21, p. 2683–2710, 2007.
- GANDELLINI, P.; ANDRIANI, F.; MERLINO, G.; D’AIUTO, F.; ROZ, L.; CALLARI, M. Complexity in the tumour microenvironment: Cancer associated fibroblast gene expression patterns identify both common and unique features of tumour-stroma crosstalk across cancer types. **Seminars in Cancer Biology**, v. 35, p. 96–106, 2015.

GOMES, F. C. A.; TORTELLI, V. P.; DINIZ, L. Glia: dos velhos conceitos às novas funções de hoje e as que ainda virão. **Estudos Avançados**. v 27.p.61-84, 2013.

HARTUNG, T.; DASTON, G. Are In Vitro Tests Suitable for Regulatory Use?. **Toxicological Sciences**, v. 111, p. 233–237, 2009.

HASSANPOUR, S. H.; DEHGhani, M. Review of cancer from perspective of molecular. **Journal of Cancer Research and Practice**, v. 4, p. 127-129, 2017.

JACOB, R. B.; ANDERSEN, T.; MCDUGAL, O. M. Accessible High-Throughput Virtual Screening Molecular Docking Software for Students and Educators. **PLoS Computational Biology**.v 8.p. 1-4, 2012.

JONES, G.; WILLETT, P.; GLEN, R. C.; LEACH, A. R.; TAYLOR, R. Development and Validation of a Genetic Algorithm for Flexible Docking. **Journal of Molecular Biology**. V 267.p. 727-748, 1997.

JUNG, T.; CHOI, Y. D.; KIM, Y.H.; LEE, J. J.; KIM, H. S.; KIM, J.S.; KIM, S.-K.; JUNG, S.; CHO, D. Immunological Characterization of Glioblastoma Cells for Immunotherapy. **Anticancer Research**, v. 33, p. 2525-2534, 2013.

LEITE, W. L. O.; OLIVEIRA FILHO, A. A. Avaliação Farmacológica de Produtos Naturais no Combate ao Câncer. **Revista Interdisciplinar em Saúde**, v.1, p.192-211, 2014.

LI, W.; SUN, H.; XU, S.; ZHU, Z.; XU, J. Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures. **Future Medicinal Chemistry**. v. 1.p. 1-30, 2017.

MARTINCORENA, I.; RAINE, K. M.; GERSTUNG, M.; DAVIES, H.; STRATTON, M. R.; CAMPBELL, P. J. Universal Patterns of Selection in Cancer and Somatic Tissues. **Cellpress**, v. 171, p.1029–1041, 2017.

METWALI, H.; ELHAKIM, A. Effects of Different Therapeutic Approaches on Diagnosis of Glioblastoma and Detection of Its Recurrence. **World EuroSurgery**, v. 109, p. 96-97, 2017.

NOCH, E.; KHALILI, K. Molecular Mechanisms of Necrosis in Glioblastoma: The Role of Glutamate Excitotoxicity. **Cancer Biology & Therapy**, v. 8, p. 1791-1797, 2009.

POMMIER, Y. Drugging Topoisomerases: Lessons and Challenges, **Acs Chemical Biology**. v. 8.p. 82-95, 2013.

RAO V. A.; Iron Chelators With Topoisomerase-Inhibitory Activity And Their Anticancer Applications. **Antioxidants & Redox Signaling**.v 18.p. 930-955, 2013.

RITTER, M.; MARTINS, R. M.; ROSA, S. A.; MALAVOLTA, J. L.; LUND, R. G.; FLORES, A. F. C.; PEREIRA, C. M. P. Green Synthesis of Chalcones and Microbiological Evaluation. **Journal of the Brazilian Chemical Society**. v 26.p.1201-1210, 2015.

SADEGHI,I.; BEHMANESH, M.; CHASHMI, N. A.; SHARIFI, M.; SOLTANI,B. M. 6-ethoxy Podophyllotoxin Induces Apoptosis Via Inhibition Of Tubb3 And Topiia Gene Expressions In 5637 And K562 Cancer Cell Lines. **Cell Journal(Yakhteh)**. V 17.p. 502-509, 2015.

SILVA, J. F. S.; MATTOS, I. E. Padrão de distribuição do câncer em cidade da zona de fronteira: tendência da mortalidade por câncer em Corumbá, Mato Grosso do Sul, no período 1980-2006. **Revista Epidemiologia e Serviços de Saúde**, v. 20, p. 65-74, 2011.

SILVA, P. A.; RIUL, S. S. Câncer de mama: fatores de risco e detecção precoce. **Revista Brasileira de Enfermagem**, v. 64, p.1016-21, 2011.

SONTHEIMER, H. A role for glutamate in growth and invasion of primary brain tumors. **Journal of Neurochemistry**, v.105, p. 287–295, 2009.

SULTANA, S.; ASIF, H. M.; NAZAR, H. M. I.; AKHTAR, N.; REHMAN, J. U.; REHMAN, R. U. **Medicinal Plants Combating Against Cancer - a Green Anticancer Approach**. **Asian Pacific Journal of Cancer Prevention**, v. 15, p. 4385-4394, 2014.

ZHAO, L.; SUN, T.; PEI, J.; OUYANG, Q. Mutation-induced protein interaction kinetics changes affect apoptotic network dynamic properties and facilitate oncogenesis. **Proceedings of the National Academy of Sciences**, v 1. p. 4046-4054, 2015.

## Anexo 1 – Normas de publicação dos respectivos periódicos



### EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Published under the auspices of the French Société de Chimie Thérapeutique (SCT)

#### AUTHOR INFORMATION PACK

#### TABLE OF CONTENTS

---

●	<b>Description</b>	<b>p.1</b>
●	<b>Audience</b>	<b>p.1</b>
●	<b>Impact Factor</b>	<b>p.1</b>
●	<b>Abstracting and Indexing</b>	<b>p.2</b>
●	<b>Editorial Board</b>	<b>p.2</b>
●	<b>Guide for Authors</b>	<b>p.3</b>



ISSN: 0223-5234

#### DESCRIPTION

---

The *European Journal of Medicinal Chemistry* is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcome critical review papers.



# EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Published under the auspices of the French Société de Chimie Thérapeutique (SCT)

## AUTHOR INFORMATION PACK

### TABLE OF CONTENTS

• Description	p.1
• Audience	p.1
• Impact Factor	p.1
• Abstracting and Indexing	p.2
• Editorial Board	p.2
• Guide for Authors	p.3



### DESCRIPTION

The *European Journal of Medicinal Chemistry* is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcome critical review papers.

A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting.

#### Benefits to authors

We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click [here](#) for more information on our [author services](#).

Please see our [Guide for Authors](#) for information on article submission. If you require any further information or help, please visit our [Support Center](#) <http://about.elsevier.com/images/EJMECH2012.gif>

### AUDIENCE

Medicinal Chemists, Pharmacologists, Pharmacists, Biochemists and Physicians.

### IMPACT FACTOR

2016: 4.519 © Thomson Reuters Journal Citation Reports 2017

## ABSTRACTING AND INDEXING

---

### BIOSIS

Elsevier BIOBASE

CNRS/Pascal

Chemical Abstracts

Current Contents/Life Sciences

MEDLINE®

EMBASE

Science Citation Index

Current Awareness in Biological Sciences

Scopus

## EDITORIAL BOARD

---

### *Editor-in-Chief*

H. Galons, Université Paris Descartes, Paris, France

### *Associate Editors*

L-H Zhang, Sch. of Pharmaceutical Sciences, Peking University, Beijing, China

R. Csuk, Dept. of Chemistry, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany

N. Moitessier, Chemistry Department, McGill University, Montreal, Quebec, Canada

T. Jonckers, Janssen Infectious Diseases - Diagnostics BVBA, Janssen Research & Development, Beerse, Belgium

P. Barraja, Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STERICEF), ,  
Università degli Studi di Palermo, Palermo, Italy

### *Honorary Editor-in-Chief*

O. Lafont, Faculté de Médecine et Pharmacie, Rouen, France

### *Editorial Advisory Board*

C.W.G. Fishwick, University of Leeds, Leeds, UK

P. Furet, Novartis International AG, Basel, Switzerland

P. G. George

T. Guzi, Blueprint Medicines, Cambridge, Massachusetts, USA

D. Hadjipavlou-Litina, Aristotle University of Thessaloniki, Thessaloniki, Greece

R. Hawley, University of California at San Francisco (UCSF), San Francisco, California, USA

R. J-R. Hwu, National Tsing Hua University, Hsinchu, Taiwan

L.H. Jones, VP, Chemical Biology, Inana Therapeutics, Boston, MA, USA

C. Kunick, Technische Universität Braunschweig, Braunschweig, Germany

C. Lasmezas, The Scripps Research Institute, Jupiter, Florida, USA

D. Lesuisse, Sanofi, Framingham, Massachusetts, USA

M. Lucas, Cubist Pharmaceuticals, Lexington, Massachusetts, USA

D. Neri, Swiss Federal Institute of Technology, Zurich, Switzerland

T. Owens, Principia Biopharma Inc., San Francisco, California, USA

M.-J. Pérez-Pérez, Instituto de Química Médica (IQM-CSIC), Madrid, Spain

J. Quan, Peking University, Beijing, China

K. Roy, Jadavpur University, Kolkata, India

J. K. Shen, Chinese Academy of Sciences (CAS), Shanghai, China

P. Singh, Guru Nanak Dev University, Amritsar, India

C.T. Supuran, Università degli Studi di Firenze, Firenze, Italy

T.T. Talele, St. John's University, Queens, New York, USA

P. Yu, Tianjin University of Science and Technology, Tianjin, China

Y.-M. Zheng, Université Pierre et Marie Curie, Paris, France

D. M. Zou, Peking University, Beijing, China

## GUIDE FOR AUTHORS

---

### *Your Paper Your Way*

We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.

**To find out more, please visit the Preparation section below.**

### INTRODUCTION

The *European Journal of Medicinal Chemistry* (EJMECH) publishes studies on all aspects of medicinal chemistry, including organic synthesis; biological behavior; pharmacological activity; drug design; QSAR; molecular modelling; drug-receptor interactions; molecular aspects of drug metabolism; pro-drug synthesis and drug targeting. The journal accepts papers from any country in this world.

### *Types of Contributions*

The journal provides a medium for publication of the following articles:

*Original papers* are full papers describing original research of high scientific level and timeliness. They are definitive reports on a full study.

*Short communications* are shorter pieces of work and report limited studies of the same level as described in original papers.

*Preliminary communications* are also limited studies but describe particularly novel and significant new findings which shall be developed further in the future.

*Laboratory notes* are focused on practical aspects. They may deal with an original synthesis of a series of compounds or with new pharmacological methods.

*Review articles* are specially commissioned by the Editors and may embrace the results of various workers in a given area or may feature recent developments from the author's own laboratory. A review that is distinguished by a novel interpretation or representation of earlier findings is especially suitable. The Editors welcome inquiries concerning the suitability of a particular topic for a review article. In addition, a book review section appears in the journal from time to time.

### *Contact Details for Submission*

The *European Journal of Medicinal Chemistry* uses a web-based online manuscript submission and review system. Authors must submit their manuscript via the online submission page <http://ees.elsevier.com/ejmech>

### *Submission checklist*

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

#### **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address

All necessary files have been uploaded:

*Manuscript:*

- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print

*Graphical Abstracts / Highlights files* (where applicable)

*Supplemental files* (where applicable)

Further considerations:

- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- A competing interests statement is provided, even if the authors have no competing interests to declare
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our [Support Center](#).

## **BEFORE YOU BEGIN**

### **Ethics in publishing**

Please see our information pages on [Ethics in publishing](#) and [Ethical guidelines for journal publication](#).

### **Human and animal rights**

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans; Uniform Requirements for manuscripts submitted to Biomedical journals. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the [ARRIVE guidelines](#) and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed.

In addition to the contents of the Directive 2010/63/EU Authors of papers submitted to EJMECH are encouraged to reduce as much as possible animal testing. Indeed, animal testing should be limited to the study of compounds that have already demonstrated enough interest in *in vitro* experiments. It should not be used as a general screening method.

### **Declaration of interest**

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. [More information](#).

### **Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see 'Multiple, redundant or concurrent publication' section of our ethics policy for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service [CrossCheck](#).

### **Contributors**

Each author is required to declare his or her individual contribution to the article: all authors must have materially participated in the research and/or article preparation, so roles for all authors should be described. The statement that all authors have approved the final article should be true and included in the disclosure.

### **Changes to authorship**

Authors are expected to consider carefully the list and order of authors **before** submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only **before** the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the **corresponding author**: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors **after** the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

#### *Article transfer service*

This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. [More information.](#)

### **Copyright**

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see [more information](#) on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. [Permission](#) of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has [preprinted forms](#) for use by authors in these cases.

For open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' ([more information](#)). Permitted third party reuse of open access articles is determined by the author's choice of [user license](#).

### **Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. [More information.](#)

#### *Elsevier supports responsible sharing*

Find out how you can [share your research](#) published in Elsevier journals.

### **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

#### *Funding body agreements and policies*

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the Open Access Publication Fee. Details of [existing agreements](#) are available online.

### **Open access**

This journal offers authors a choice in publishing their research:

#### **Subscription**

- Articles are made available to subscribers as well as developing countries and patient groups through our universal access programs.

- No open access publication fee payable by authors.

#### **Open access**

- Articles are freely available to both subscribers and the wider public with permitted reuse.
- An open access publication fee is payable by authors or on their behalf, e.g. by their research funder or institution.

Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards.

For open access articles, permitted third party (re)use is defined by the following Creative Commons user licenses:

#### *Creative Commons Attribution (CC BY)*

Lets others distribute and copy the article, create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), include in a collective work (such as an anthology), text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

#### *Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)*

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The open access publication fee for this journal is **USD 3250**, excluding taxes. Learn more about Elsevier's pricing policy: <https://www.elsevier.com/openaccesspricing>.

#### *Green open access*

Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our [green open access page](#) for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. [Find out more.](#)

This journal has an embargo period of 24 months.

#### *Elsevier Publishing Campus*

The Elsevier Publishing Campus ([www.publishingcampus.com](http://www.publishingcampus.com)) is an online platform offering free lectures, interactive training and professional advice to support you in publishing your research. The College of Skills training offers modules on how to prepare, write and structure your article and explains how editors will look at your paper when it is submitted for publication. Use these resources, and more, to ensure that your submission will be the best that you can make it.

#### *Language (usage and editing services)*

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](#) available from Elsevier's WebShop.

#### **Submission**

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

#### *Referees*

Please submit the names and institutional e-mail addresses of several potential referees. For more details, visit our [Support site](#). Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.

## PREPARATION

### NEW SUBMISSIONS

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

#### *References*

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

#### *Formatting requirements*

There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.

If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.

Divide the article into clearly defined sections.

#### *Figures and tables embedded in text*

Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file. The corresponding caption should be placed directly below the figure or table.

### Peer review

This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. [More information on types of peer review.](#)

### REVISED SUBMISSIONS

#### *Use of word processing software*

Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the [Guide to Publishing with Elsevier](#)). See also the section on [Electronic artwork](#).

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

#### *Essential title page information*

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.

• **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**

• **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

#### *Graphical abstract*

A graphical abstract is mandatory for this journal. It should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership online. Authors must provide images that clearly represent the work described in the article. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view [Example Graphical Abstracts](#) on our information site.

Authors can make use of Elsevier's [Illustration Services](#) to ensure the best presentation of their images also in accordance with all technical requirements.

#### *Highlights*

Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). You can view [example Highlights](#) on our information site.

#### **Keywords**

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

#### *Abbreviations*

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

#### **Experimental**

Analytical data should be included for examination by the editor and referees. However, these data will not be printed if they agree within within  $\pm 0.4\%$  with calculated values, but may be noted as follows: 'Anal. C<sub>14</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub> (C, H, N, O)', with the mentioning under Experimental protocols: 'Analyses indicated by the symbols of the elements or functions were within  $\pm 0.4\%$  of the theoretical values'.

#### **Characterization of prepared compounds**

Organic compounds:

Sufficient experimental information should be given by the authors. In particular "supplementary material for publication online" should be constructed for all papers which should at least include representative <sup>1</sup>H and <sup>13</sup>C NMR spectra. Metal complexes:

X-Ray crystal structural determinations are required for metal complexes.

#### *Acknowledgements*

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

#### *Formatting of funding sources*

List funding sources in this standard way to facilitate compliance to funder's requirements:

**Funding:** This work was supported by the National Institutes of Health [grant numbers xxxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

### **Nomenclature**

The author is responsible for providing the correct nomenclature which must be consistent and unambiguous. The use of chemical names for drugs is preferred.

### **Math formulae**

Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

### **Footnotes**

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article.

### **Artwork**

#### **Electronic artwork**

##### **General points**

- Make sure you use uniform lettering and sizing of your original artwork.
  - Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
  - Number the illustrations according to their sequence in the text.
  - Use a logical naming convention for your artwork files.
  - Indicate per figure if it is a single, 1.5 or 2-column fitting image.
  - For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
  - Please note that individual figure files larger than 10 MB must be provided in separate source files.
- A detailed guide on electronic artwork is available.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

##### **Formats**

Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.

TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.

TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.

TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

##### **Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
- Supply files that are too low in resolution.
- Submit graphics that are disproportionately large for the content.

##### **Color artwork**

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive**

**Information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or online only. Further information on the preparation of electronic artwork.

#### *Figure captions*

Ensure that each illustration has a caption. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

#### *Text graphics*

Text graphics may be embedded in the text at the appropriate position. If you are working with LaTeX and have such features embedded in the text, these can be left. See further under Electronic artwork.

#### **Tables**

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

#### **References**

##### *Citation in text*

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

##### *Web references*

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

##### *Data references*

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

##### *References in a special issue*

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

##### *Reference management software*

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley and Zotero, as well as EndNote. Using the word processor plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide.

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

<http://open.mendeley.com/use-citation-style/european-journal-of-medicinal-chemistry>

When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

### Reference formatting

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

#### Reference style

**Text:** Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.

**Example:** '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....'

**List:** Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

#### Examples:

**Reference to a journal publication:**

[1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a scientific article, *J. Sci. Commun.* 163 (2010) 51–59.

**Reference to a book:**

[2] W. Strunk Jr., E.B. White, *The Elements of Style*, fourth ed., Longman, New York, 2000.

**Reference to a chapter in an edited book:**

[3] G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: B.S. Jones, R.Z. Smith (Eds.), *Introduction to the Electronic Age*, E-Publishing Inc., New York, 2009, pp. 281–304.

**Reference to a website:**

[4] Cancer Research UK, *Cancer statistics reports for the UK*. <http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/>, 2003 (accessed 13 March 2003).

**Reference to a dataset:**

[dataset] [5] M. Oguro, S. Imahiro, S. Saito, T. Nakashizuka, Mortality data for Japanese oak wilt disease and surrounding forest compositions, *Mendeley Data*, v1, 2015. <https://doi.org/10.17632/xwj98nb39r.1>.

### Video

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. . In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our [video instruction pages](#). Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

### Supplementary material

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

## RESEARCH DATA

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the [research data page](#).

### *Data linking*

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](#).

For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

### *Open data*

This journal supports Open data, enabling authors to submit any raw (unprocessed) research data with their article for open access publication under the CC BY license. [More information](#).

### *Mendeley Data*

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. Before submitting your article, you can deposit the relevant datasets to *Mendeley Data*. Please include the DOI of the deposited dataset(s) in your main manuscript file. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals page](#).

### *Data in Brief*

You have the option of converting any or all parts of your supplementary or additional raw data into one or multiple data articles, a new kind of article that houses and describes your data. Data articles ensure that your data is actively reviewed, curated, formatted, indexed, given a DOI and publicly available to all upon publication. You are encouraged to submit your article for *Data in Brief* as an additional item directly alongside the revised version of your manuscript. If your research article is accepted, your data article will automatically be transferred over to *Data in Brief* where it will be editorially reviewed and published in the open access data journal, *Data in Brief*. Please note an open access fee of 500 USD is payable for publication in *Data in Brief*. Full details can be found on the *Data in Brief* website. Please use [this template](#) to write your Data in Brief.

### *MethodsX*

You have the option of converting relevant protocols and methods into one or multiple *MethodsX* articles, a new kind of article that describes the details of customized research methods. Many researchers spend a significant amount of time on developing methods to fit their specific needs or setting, but often without getting credit for this part of their work. *MethodsX*, an open access journal, now publishes this information in order to make it searchable, peer reviewed, citable and reproducible. Authors are encouraged to submit their *MethodsX* article as an additional item directly alongside the revised version of their manuscript. If your research article is accepted, your methods article will

automatically be transferred over to MethodsX where it will be editorially reviewed. Please note an open access fee is payable for publication in MethodsX. Full details can be found on the MethodsX website. Please use [this template](#) to prepare your MethodsX article.

#### *Data statement*

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement page](#).

### **ARTICLE ENRICHMENTS**

#### *AudioSlides*

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. [More information and examples are available](#). Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

#### *Chemical Compound Viewer (Reaxys)*

You can enrich your article with visual representations, links and details for those chemical structures that you define as the main chemical compounds described. Please [follow the instructions](#) to learn how to do this.

#### *3D molecular models*

You can enrich your online articles by providing 3D molecular models (optional) in PDB, PSE or MOL/MOL2 format, which will be visualized using the interactive viewer embedded within the article. Using the viewer, it will be possible to zoom into the model, rotate and pan the model, and change display settings. Submitted models will also be available for downloading from your online article on ScienceDirect. Each molecular model will have to be uploaded to the online submission system separately, via the '3D molecular models' submission category. [More information](#).

#### *Interactive plots*

This journal enables you to show an Interactive Plot with your article by simply submitting a data file. [Full instructions](#).

### **AFTER ACCEPTANCE**

#### *Online proof correction*

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

#### *Offprints*

The corresponding author will, at no cost, receive a customized [Share Link](#) providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the [offprint order form](#) which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's [Webshop](#). Corresponding authors who have published their article open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

## **AUTHOR INQUIRIES**

Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch. You can also check the status of your submitted article or find out when your accepted article will be published.

© Copyright 2014 Elsevier | <http://www.elsevier.com>